Myeloproliferative Neoplasms Clinical Trial
Official title:
A Phase II Study of the HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
The purpose of this study is to test a new drug called AUY922. AUY922 is not FDA-approved.
AUY922 is a new kind of drug that attacks a protein called HSP90. HSP90 is found in both
normal and cancer cells, but the investigators think it is more important in cancer cells.
This study will see if AUY922 helps people with myelofibrosis, essential thrombocythemia and
polycythemia vera. This study will also see if AUY922 is safe in people with myelofibrosis,
essential thrombocythemia and polycythemia vera. It will find out what effects, good and/or
bad, AUY922 has on the patient and the disease. The researchers hope that this study will
help them to find better treatments for primary myelofibrosis, essential thrombocythemia and
polycythemia vera.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04866056 -
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05936359 -
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
|
Phase 1 | |
| Completed |
NCT02084563 -
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
|
Phase 2 | |
| Recruiting |
NCT04339400 -
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
|
Phase 1 | |
| Completed |
NCT02125318 -
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
|
Phase 2 | |
| Not yet recruiting |
NCT06291987 -
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
|
Phase 1 | |
| Recruiting |
NCT03314974 -
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
|
Phase 2 | |
| Completed |
NCT03075826 -
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
|
Phase 2 | |
| Recruiting |
NCT02823210 -
Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
|
||
| Not yet recruiting |
NCT06313593 -
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
|
Phase 1 | |
| Recruiting |
NCT05444530 -
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
|
Phase 1 | |
| Recruiting |
NCT03912064 -
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
|
Phase 1 | |
| Terminated |
NCT02393248 -
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
|
Phase 1/Phase 2 | |
| Completed |
NCT02076191 -
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04761770 -
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
|
Phase 2 | |
| Recruiting |
NCT06034002 -
A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms
|
Phase 1 | |
| Completed |
NCT00949364 -
Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
|
Phase 2 | |
| Completed |
NCT00053196 -
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03618485 -
Registry of Patients With MPNs in Taiwan
|